

## SUPPLEMENTARY TABLES

**Supplementary table 1: National (United Kingdom) criteria for treatment in patients with wet AMD.**

National Institute of Health and Care Excellence funding guidance for patients treated with aflibercept

- Best-corrected visual acuity is between 6/12 and 6/96
- No permanent structural damage to the central fovea
- Lesion size is less than or equal to 12 disc areas in greatest linear dimension
- Evidence of recent presumed disease progression (blood vessel growth, as indicated by fluorescein angiography, or recent visual acuity changes)
- Best-corrected visual acuity is between 6/12 and 6/96 (approximate ETDRS letter score of 73 to 25 letters inclusive)

**Supplementary table 2. Baseline data of all eyes at baseline and end point.**

	Demographic data of all eyes at baseline				
		Total analysis of all eyes – 3 years follow up			
	All eyes included in the analysis (completing 1 year of follow up)	Lost to follow up between year 1 and 2	Lost to follow up between year 2 and 3	Completing 3 years follow-up	P
No. of eyes	148	17	23	108	P > 0.05
No. of patients	139	16	21	102	
Female (%)	58.9%	41.1%	62.8%	59.2%	
Mean baseline age (SD), years	80.6±8.3	81.6±8.1	81.4±10.2	80.3±7.9	
Mean baseline VA (Snellen; SD)	54.4 ± 16	49.2±18.4	56±17.9	54.9±15.2	
Baseline VA ≥ 73 letters (20/40; %)	10.8%	0%	17.4%	10.2%	
Baseline VA ≤ 35 letters (20/200; %)	19.6%	29.4%	21.7%	17.6%	
Central Macular thickness	300.3 ± 92.6	318.8±119	299.2±84.6	297.4±89.9	
	Angiographic lesion type , %				
Occult	65.9%	64.4%	65.7%	57.4%	
Classic component	22.5%	29.8%	25.7%	29.6%	
Other	5.6%	5.8%	5.7%	4.6%	
Not recorded	6%	0%	2.8%	8.3%	